Company: ELV
Filing Date: 2025-09-09
Form Type: 424B3
Source: 0001193125-25-199226
Chunk: 0

Company: Elevance Health, Inc.
Filing Date: 2025-09-09
Form: 424B3
Chunk 0
---
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-275251 PROSPECTUS SUPPLEMENT (To Prospectus dated November 1, 2023) $3,000,000,000 $750,000,000 4.000% Notes due 2028 $750,000,000 4.600% Notes due 2032 $1,000,000,000 5.000% Notes due 2036 $500,000,000 5.700% Notes due 2055 The 4.000% Notes due 2028, which we refer to as the 2028 notes, will mature on September 15, 2028, the 4.600% Notes due 2032, which we refer to as the 2032 notes, will mature on September 15, 2032, the 5.000% Notes due 2036, which we refer to as the 2036 notes, will mature on January 15, 2036, and the 5.700% Notes due 2055, which we refer to as the 2055 notes, will mature on September 15, 2055. We refer to the 2028 notes, the 2032 notes, the 2036 notes and the 2055 notes collectively as the notes. We will pay interest on the 2028 notes, the 2032 notes and the 2055 notes on March 15 and September 15 of each year, commencing March 15, 2026. We will pay interest on the 2036 notes on January 15 and July 15 of each year, commencing January 15, 2026. We may redeem the notes of any series at our option, in whole or in part, at any time and from time to time, at the applicable redemption prices discussed under the caption “ Description of the Notes—Optional Redemption.” If we experience a change of control triggering event and have not otherwise elected to redeem the notes, we will be required to offer to repurchase the notes from holders as described under the caption “ Description of the Notes—Repurchase Upon a Change of Control.” The notes will be our unsecured and unsubordinated obligations and will rank equally with our other unsecured and unsubordinated indebtedness from time to time outstanding. We do not intend to list the notes on any national securities exchange. Investing in the notes involves risks. See “ Risk Factors” beginning on page